Back to first-pass browser

First-pass extracted concept

gene-edited hematopoietic stem cells

Candidate: concept label1 source documents3 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

Gene-edited HSCs hold significant promise for treating leukemia and lymphoma, offering long-term immune persistence and tumor clearance.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1engraftment strategysupports2025Source 1DOIPubMed

Preconditioning regimens improved engraftment success for gene-edited HSC therapies in the reviewed evidence.

Claim 2review summarysupports2025Source 1DOIPubMed

Gene-edited hematopoietic stem cells show promising preclinical efficacy for leukemia and lymphoma treatment.

Claim 3translation barriersupports2025Source 1DOIPubMed

Clinical translation of gene-edited HSC therapies is limited by gene delivery efficiency, safety, and engraftment challenges.